The FDA updated a warning on the label of esketamine nasal spray (Spravato) about the long-term cognitive and memory impairments that have been reported with ketamine misuse or abuse. New 3-year ...

Esketamine nasal spray (Spravato) monotherapy was helpful in improving symptoms of treatment-resistant depression, a ...

Manufacturer Janssen says Esketamine can lift a patient's mood within 24 hours of use. The drug is intended for patients who have not responded to two other, conventional antidepressants which can ...

An estimated one-third of patients with major depressive disorder have treatment-resistant depression (TRD), characterized by ...